The estimated Net Worth of Daniel L Cohen is at least $8.42 Tisíc dollars as of 15 May 2018. Daniel Cohen owns over 7,900 units of Zevra Therapeutics Inc stock worth over $8,425 and over the last 8 years Daniel sold KMPH stock worth over $0.
Daniel has made over 7 trades of the Zevra Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Daniel bought 7,900 units of KMPH stock worth $50,955 on 15 May 2018.
The largest trade Daniel's ever made was buying 10,000 units of Zevra Therapeutics Inc stock on 2 September 2016 worth over $47,500. On average, Daniel trades about 4,489 units every 69 days since 2016. As of 15 May 2018 Daniel still owns at least 1,450 units of Zevra Therapeutics Inc stock.
You can see the complete history of Daniel Cohen stock trades at the bottom of the page.
Daniel's mailing address filed with the SEC is 2500 Crosspark Rd, Coralville, IA 52241, USA.
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney a Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include: